# Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

> **NCT06606808** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Medical Center Groningen** · enrollment: 18 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)
- Crohn Disease (CD)

## Interventions

- **DRUG:** Risankizumab-800CW 4.5 mg
- **DRUG:** Risankizumab-800CW 15 mg
- **DRUG:** Risankizumab-800CW 25 mg
- **DRUG:** Risankizumab-800CW optimal dose

## Key facts

- **NCT ID:** NCT06606808
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2025-08
- **Final completion:** 2025-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06606808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06606808, "Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06606808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*